(Alliance News) - Hedge fund Citadel has made a GBP305 million bet against pharmaceuticals firm GSK PLC, the biggest short position against the company in more than a decade, according to the ...

Hedge fund Citadel has made a £305mn bet against drugmaker GSK, the biggest short position against the company in more than a decade.

ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (GSK), with Pfizer Inc. and Shionogi as shareholders, is pleased to announce it has successfully completed ...

Human immunodeficiency virus (HIV) is a virus that attacks the body's immune system. HIV is a manageable chronic condition. With treatment, people living with HIV can have long and healthy lives.

We think its portfolio and pipeline support a wide moat, and with the HCV market stabilizing, Gilead needs strong continued innovation in HIV, solid oncology pipeline data, and smart future ...

Gilead Sciences, Inc. GILD reported better-than-expected fourth-quarter results and provided an upbeat guidance for 2025.

Morgan Stanley (NYSE:MS) initiated coverage on shares of GlaxoSmithKline (NYSE:GSK:LN) (NYSE: GSK), a $72.5 billion pharmaceutical giant with a 25-year track record of consistent dividend payments, ...

GSK, a British drugmaker, recently beat Q4 earnings estimates. The company is our FDI of the Month January 2025.

To offer further encouragement, Dame Emma Walmsley, the company’s chief, offered a more optimistic outlook than expected for ...

The Indian Pharmaceuticals Market continued to deliver healthy growth at 8.7% year-on-year in January 2025, against 7.7% year ...